{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:18:32Z","timestamp":1778645912983,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01076-w","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T12:43:38Z","timestamp":1718109818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Performance of newer myeloma staging systems in a contemporary, large patient cohort"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel M.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine H.","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-3518","authenticated-orcid":false,"given":"Gregory S.","family":"Calip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Parrinello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"1076_CR1","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1076_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0254-0","volume":"9","author":"TM Schmidt","year":"2019","unstructured":"Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9:94.","journal-title":"Blood Cancer J"},{"key":"1076_CR3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.3324\/haematol.2021.280566","volume":"108","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Lauwers-Cances V, Perrot A, Cazaubiel T, Chretien ML, Moreau P, et al. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma. Haematologica. 2023;108:1374\u201384.","journal-title":"Haematologica"},{"key":"1076_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00611-x","volume":"12","author":"NH Abdallah","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12:21.","journal-title":"Blood Cancer J"},{"key":"1076_CR5","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"1076_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159\u201370.","journal-title":"Leukemia"},{"key":"1076_CR7","doi-asserted-by":"crossref","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2020.03.16.20037143. 2023.","DOI":"10.1101\/2020.03.16.20037143"},{"key":"1076_CR8","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, Agrawal M, Estevez M, Estola E, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv preprint arXiv:200109765. 2020."},{"key":"1076_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hon.3090","volume":"41","author":"H Chen","year":"2023","unstructured":"Chen H, Zhou N, Hu X, Wang D, Wei W, Peng R, et al. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis. Hematol Oncol. 2023;41:139\u201346.","journal-title":"Hematol Oncol"},{"key":"1076_CR10","doi-asserted-by":"publisher","first-page":"2208914","DOI":"10.1080\/16078454.2023.2208914","volume":"28","author":"Y Cao","year":"2023","unstructured":"Cao Y, Gong Y, Zhou X, Sun C. Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients. Hematology. 2023;28:2208914.","journal-title":"Hematology"},{"key":"1076_CR11","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1097\/CM9.0000000000002735","volume":"136","author":"W Yan","year":"2023","unstructured":"Yan W, Fan H, Xu J, Liu J, Li L, Du C, et al. Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma. Chin Med J. 2023;136:1744\u20136.","journal-title":"Chin Med J"},{"key":"1076_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12185-023-03541-x","volume":"117","author":"M Mizuguchi","year":"2023","unstructured":"Mizuguchi M, Okamoto Y, Yagi H, Kagawa K, Sekimoto E, Shibata H, et al. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice. Int J Hematol. 2023;117:718\u201328.","journal-title":"Int J Hematol"},{"key":"1076_CR13","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.1182\/bloodadvances.2023011096","volume":"7","author":"W Guo","year":"2023","unstructured":"Guo W, Zhan A, Mery DE, Munshi MN, Makhoul O, Baily C, et al. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS. Blood Adv. 2023;7:6676\u201384.","journal-title":"Blood Adv"},{"key":"1076_CR14","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","volume":"103","author":"S Thorsteinsdottir","year":"2018","unstructured":"Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018;103:e412\u20135.","journal-title":"Haematologica"},{"key":"1076_CR15","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","volume":"106","author":"N Weinhold","year":"2021","unstructured":"Weinhold N, Salwender HJ, Cairns DA, Raab MS, Waldron G, Blau IW, et al. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2596 trial patients. Haematologica. 2021;106:2754\u20138.","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01076-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01076-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01076-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T12:47:14Z","timestamp":1718110034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01076-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1076"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01076-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"24 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following conflicts of interest: Mohyuddin: MashupMD: Royalties for writing, and institutional funding from Janssen for Dr. Mohyuddin being a site principal investigator for a Phase III trial. Rubinstein: Consulting with Janssen, Sanofi, Roche Diagnostics, and EUSA Pharma. Kumar: Consulting\/advisory board participation (with no personal payments) with AbbVie, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX, and Beigene. Fonseca: Antegene: Membership on an entity\u2019s Board of Directors or advisory committees; Regeneron: Consultancy; Oncotracker: Membership on an entity\u2019s Board of Directors or advisory committees; Millenium: Consultancy; Binding Site: Consultancy; Janssen: Consultancy; Juno: Consultancy; Merck: Consultancy; Pfizer: Consultancy; Aztrazenica: Consultancy; Kite: Consultancy; Adaptive Biotechnologies: Membership on an entity\u2019s Board of Directors or advisory committees; Sanofi: Consultancy; BMS (Celgene): Consultancy; Takeda: Consultancy; AMGEN: Consultancy; FISH: Patents & Royalties: FISH; AZBio: Membership on an entity\u2019s Board of Directors or advisory committees; Bayer: Consultancy; Pharmacyclics: Consultancy; Caris Life Sciences: Membership on an entity\u2019s Board of Directors or advisory committees; Adaptive Biotechnologies: Consultancy; AbbVie: Consultancy. Calip: Roche: Current equity holder in publicly-traded company. Wang: Flatiron Health: Current Employment; Roche: Current equity holder in publicly-traded company. Parrinello: Flatiron Health: Consultancy; Clue by Biowink: Consultancy; Evidation Health: Consultancy; EQRx: Consultancy; Roche: Current equity holder in publicly-traded company; Medicus Economics: Consultancy; Jazz Pharmaceuticals: Consultancy; Omada Health: Consultancy; Plinth: Consultancy; TTI Health: Consultancy; Canopy Care: Consultancy; IQ Solutions: Consultancy; Outcomes4Me: Consultancy. Sborov: Gilead: Research Funding; Arcellx: Consultancy, Research Funding; Bioline: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; BMS: Consultancy; Abbvie: Consultancy; Sanofi: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Amgen: Research Funding; GSK: Consultancy, Research Funding; Cantex: Research Funding; RocheX: Research Funding.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was IRB approved by the University of Utah, as part of an agreement with Flatiron (and did not directly have any encounter with human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"95"}}